Head-to-head evidence
AZD6234 vs petrelintide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
AZD6234
Developed by AstraZeneca
NCT06595238 · Phase 2 · completed
Randomized, quadruple-blind, placebo-controlled Phase 2 trial in 262 participants with obesity or overweight; primary endpoint Percent change in body weight from baseline to week 26. Completed December 2025; numerical results not yet posted to the registry, so the grade is the design ceiling for a completed controlled study without results.
Next expected readout: October 2026 · NCT07017179 (registry estimate)
petrelintide
Developed by Zealand Pharma and partners
NCT06662539 · Phase 2 · completed
The study was randomized and double-blind, used matching placebo, and enrolled 493 participants. Its primary clinical endpoint was change in body weight, but the outcome comparison is not yet available because results have not been posted.
Next expected readout: November 2027 · NCT07589686 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD6234's landscape · petrelintide's landscape